Open AccessCOVID‐19: A review of therapeutics under investigation
Author(s) -
Crosby James C.,
Heimann Matthew A.,
Burleson Samuel L.,
Anzalone Brendan C.,
Swanson Jonathan F.,
Wallace Douglas W.,
Greene Christopher J.
Publication year - 2020
Publication title -
journal of the american college of emergency physicians open
Language(s) - English
Resource type - Journals
ISSN - 2688-1152
DOI - 10.1002/emp2.12081
Subject(s) - lopinavir , covid-19 , chloroquine , ritonavir , medicine , clinical trial , hydroxychloroquine , pharmacology , intensive care medicine , lopinavir/ritonavir , virology , outbreak , immunology , antiretroviral therapy , human immunodeficiency virus (hiv) , viral load , disease , malaria , infectious disease (medical specialty)
The COVID‐19 outbreak has disrupted global health care networks and caused thousands of deaths and an international economic downturn. Multiple drugs are being used on patients with COVID‐19 based on theoretical and in vitro therapeutic targets. Several of these therapies have been studied, but many have limited evidence behind their use, and clinical trials to evaluate their efficacy are either ongoing or have not yet begun. This review summarizes the existing evidence for medications currently under investigation for treatment of COVID‐19, including remdesivir, chloroquine/hydroxychlorquine, convalescent plasma, lopinavir/ritonavir, IL‐6 inhibitors, corticosteroids, and angiotensin‐converting enzyme inhibitors.